▶ IPA / CJC-1295 · SUBTOPIC · MECHANISM
IPA / CJC-1295 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Two-peptide pair. Ipamorelin selectively engages the ghrelin receptor (GHS-R1a). CJC-1295 (No DAC) is a GHRH(1-29) analog. Together they amplify the GH pulse.
PHARMACOKINETIC HALF-LIFE
Reported half-life for IPA / CJC-1295: Ipamorelin ~2 hr · CJC-1295 No DAC ~30 min. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
IPA / CJC-1295 is tagged in 1 mechanism category on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: tesamorelin and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Ipamorelin selectively binds GHS-R1a without significant cortisol/prolactin elevation (Raun et al. 1998).
Beck et al. 2014 (PMID 25331030, NCT00672074) Phase 2 trial showed numerical but not statistically significant reduction in time-to-first-bowel-movement. Helsinn/the originator pharma sponsor sponsor program discontinued.
Teichman et al. 2006 (ConjuChem Phase 1/2) reported sustained IGF-1 elevation. Two deaths in lipodystrophy trial halted that program.
Community-reported research protocols. No completed Phase 3 trials.
MECHANISM Q+A
▶ What is ipamorelin / CJC-1295?
Ipamorelin / CJC-1295 is a two-peptide research pair commonly co-administered. Ipamorelin is a selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). CJC-1295 (No DAC variant) is a stabilized GHRH(1-29) analog. The pair amplifies the GH pulse via dual-pathway activation.
▶ What is the difference between CJC-1295 with DAC and No DAC?
CJC-1295 with DAC carries a maleimidopropionic-acid (MPA) linker that covalently binds plasma albumin in vivo, extending half-life to roughly one week. CJC-1295 No DAC (also called modified GRF(1-29) or Mod GRF 1-29) lacks the MPA linker and has the same short half-life as native GHRH (~30 min). Most current research uses the No-DAC variant; the With-DAC ConjuChem trial program was halted.
▶ Why is ipamorelin stacked with CJC-1295?
Ipamorelin and CJC-1295 activate two complementary upstream pathways for GH release. Ipamorelin engages the ghrelin receptor; CJC-1295 engages the GHRH receptor. Combined stimulation produces synergistic GH pulses larger than either alone in animal-model studies.
▶ What is the half-life of ipamorelin?
Approximately 2 hours plasma half-life. The pulse-and-decay profile lasts roughly 3–4 hours in published pharmacokinetic studies.
▶ What is the half-life of CJC-1295 No DAC?
Approximately 30 minutes · the same as native GHRH(1-29). The stabilizing substitutions resist DPP-IV cleavage but do not add albumin tethering. Hence the need for multiple daily injections in research protocols.
▶ Does ipamorelin / CJC-1295 stack with the triple-receptor incretin agonist?
Different mechanisms; no published combination data. the triple-receptor incretin agonist is an incretin agonist (GLP-1R, GIPR, GCGR). Ipamorelin/CJC-1295 act on the GH-axis. Theoretical complementarity exists; no clinical RCT validates the combination.
▶ Side effects of ipamorelin / CJC-1295?
Most common in community-reported research protocols: mild injection-site reactions, transient hunger (ghrelin-receptor component), mild flushing, rare water retention. Safer profile than older non-selective GHS like GHRP-6.
CITED LITERATURE
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009. PMID 19289567. link
- Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19